Julie Bauman, Stephanie Blank to lead NRG Oncology Cancer Prevention & Control Committee

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

Jane Figueiredo was appointed co-leader of the Cancer Prevention and Control Program at Cedars-Sinai Cancer Center.

October 11, 2024

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Jose and Irma Russo dedicated their careers to investigating breast cancer, its causes, and potential prevention measures.

September 27, 2024

Vol.50 No.36

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

The NRG Oncology NSABP B-39/RTOG 0413 clinical trial compared whole-breast irradiation to accelerated partial-breast irradiation and determined that APBI was not statistically equivalent to WBI in local tumor control. The secondary outcome for the trial was quality-of-life.

September 20, 2024

Vol.50 No.35

Clinical Trials & Tribulations

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.

September 06, 2024

Vol.50 No.33

By Rebecca Sutphen, Sue Friedman and Jon Florin

Obituary

Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82

Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.

June 28, 2024

Vol.50 No.26

By Jacquelyn Cobb

Julie Bauman, Stephanie Blank to lead NRG Oncology Cancer Prevention & Control Committee

YOU MAY BE INTERESTED IN

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Group chairs propose funding strategy to jump-start correlative studies

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82

Renew today!

Subscriber content

Login

Julie Bauman, Stephanie Blank to lead NRG Oncology Cancer Prevention & Control Committee

YOU MAY BE INTERESTED IN

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Group chairs propose funding strategy to jump-start correlative studies

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82

Login

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?